Shots:

• The companies signed an agreement to manufacture movantik for opioid-induced constipation and RHB-204- currently in a P-III US study as a stand-alone 1L treatment for pulmonary NTM disease
• Movantik is the leading prescribed oral peripherally acting mu-opioid receptor antagonist (PAMORA) in the US specifically designed to treat OIC in adult patients with chronic non-cancer pain
• RHB-204 has received FDA Fast Track- OD- and QIDP designations aimed at accelerating development and FDA review and extending the US market exclusivity to a potential total of 12 yrs. (to be granted at the time of FDA approval)

 ­ Ref: RedHill | Image: RedHill